Literature DB >> 23482934

Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A.

Manuel D Carcao1, H Marijke van den Berg, Rolf Ljung, Maria Elisa Mancuso.   

Abstract

Phenotypic variability is well recognized in severe hemophilia A. A few studies, mainly in adults treated lifelong on demand, suggest that bleeding phenotype correlates with factor VIII gene (F8) mutation type. Because treatment regimens influence outcomes to a large extent, examining bleeding phenotype during the first years of life may be the most suitable way to define this variability. We set out to analyze the very early phenotypic expression of severe hemophilia A in 621 consecutively enrolled, well-characterized previously untreated patients and to correlate this with patients' F8 mutation. Detailed information was collected on bleeds and treatment of the first 75 exposure days or until inhibitor development. F8 mutation type was known for 531 patients; 402 had null mutations and 129 had non-null mutations. Considering only patients who had not started prophylaxis or developed an inhibitor before select bleeding events, we found that patients with null mutations experienced their first bleed and first joint bleed at younger median ages than patients with non-null mutations (9.7 vs 10.9 months and 13.8 vs 16.1 months, respectively). We conclude that F8 mutation type accounts for only a small component of the significant phenotypic variability found among patients with severe hemophilia A.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23482934     DOI: 10.1182/blood-2012-11-469403

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

Review 1.  Genomics of bleeding disorders.

Authors:  A C Goodeve; A Pavlova; J Oldenburg
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

2.  The importance of genetic factors for the development of arthropathy: a longitudinal study of children and adolescents with haemophilia A.

Authors:  Edward D Gomperts; John Schwarz; Sharyne M Donfield; Alice E Lail; Jan Astermark; W Keith Hoots; Cheryl A Winkler; Erik Berntorp
Journal:  Thromb Haemost       Date:  2016-12-08       Impact factor: 5.249

3.  A mathematical model of coagulation under flow identifies factor V as a modifier of thrombin generation in hemophilia A.

Authors:  Kathryn G Link; Michael T Stobb; Matthew G Sorrells; Maria Bortot; Katherine Ruegg; Marilyn J Manco-Johnson; Jorge A Di Paola; Suzanne S Sindi; Aaron L Fogelson; Karin Leiderman; Keith B Neeves
Journal:  J Thromb Haemost       Date:  2019-11-01       Impact factor: 5.824

4.  Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative.

Authors:  Jill M Johnsen; Shelley N Fletcher; Haley Huston; Sarah Roberge; Beth K Martin; Martin Kircher; Neil C Josephson; Jay Shendure; Sarah Ruuska; Marion A Koerper; Jaime Morales; Glenn F Pierce; Diane J Aschman; Barbara A Konkle
Journal:  Blood Adv       Date:  2017-05-18

5.  Recombinant factor VIIa addition to haemophilic blood perfused over collagen/tissue factor can sufficiently bypass the factor IXa/VIIIa defect to rescue fibrin generation.

Authors:  R Li; K A Panckeri; P F Fogarty; A Cuker; S L Diamond
Journal:  Haemophilia       Date:  2017-05-05       Impact factor: 4.287

6.  Genotype-cancer association in patients with Fanconi anemia due to pathogenic variants in FANCD1 (BRCA2) or FANCN (PALB2).

Authors:  Lisa J McReynolds; Kajal Biswas; Neelam Giri; Shyam K Sharan; Blanche P Alter
Journal:  Cancer Genet       Date:  2021-10-04

Review 7.  Novel blood coagulation molecules: Skeletal muscle myosin and cardiac myosin.

Authors:  Hiroshi Deguchi; Shravan Morla; John H Griffin
Journal:  J Thromb Haemost       Date:  2020-10-25       Impact factor: 5.824

8.  Microfluidic assay of hemophilic blood clotting: distinct deficits in platelet and fibrin deposition at low factor levels.

Authors:  T V Colace; P F Fogarty; K A Panckeri; R Li; S L Diamond
Journal:  J Thromb Haemost       Date:  2014-02       Impact factor: 5.824

Review 9.  Microfluidic technology as an emerging clinical tool to evaluate thrombosis and hemostasis.

Authors:  Brian R Branchford; Christopher J Ng; Keith B Neeves; Jorge Di Paola
Journal:  Thromb Res       Date:  2015-05-21       Impact factor: 3.944

10.  Mutations in intron 1 and intron 22 inversion negative haemophilia A patients from Western India.

Authors:  Preethi S Nair; Shrimati D Shetty; S Chandrakala; Kanjaksha Ghosh
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.